Pharm Exec 50: The Winners’ Circle

Conferences, congresses, and the digital discussions kicked off by those events create a halo effect that amplifies scientific information more so than other scientific activities.

Jan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.

Amid shifting operating dynamics in recent years, demands for external expertise have fluctuated—leaving those arrangements that mix innovation and agility likely to win out in pharma decision-making.

With the increasing adoption of COAs, the importance of standardization across training, collection, and implementation to ensure high quality and consistent data collection has become apparent in recent decades.

As the second half of 2024 begins, an industry expert discusses how mergers and acquisitions are trending in the pharma industry.

Pharmaceutical companies are seeing the benefits of being able to outsource entire functions through functional service providers.